Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

ABSTRACT:

Background

Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) for 6 weeks achieves sustained virologic response (SVR) rates of 95% in some patients. If effective, shorter therapeutic courses could improve adherence and treatment costs.

Objective

To determine factors predictive of SVR to 4 weeks of DAA treatment in patients with stage F0 to F2 liver fibrosis.

Design

Open-label, nonrandomized, phase 2a trial. (Clinical Trials.gov: NCT01805882).

Setting

Single-center.

Patients

50 treatment-naive and predominantly African American patients with HCV genotype 1 infection and early-stage liver fibrosis were sequentially enrolled into 2 treatment groups.

Intervention

25 participants received a 3-drug regimen consis

SUBMITTER: Kohli A 

PROVIDER: S-EPMC10725568 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature